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Abstract: 
Cysticercosis is a public health problem in several developing countries. The oncosphere protein TSOL18 is the most immunogenic and protective antigen ever 
reported against porcine cysticercosis, although no specific epitope has been identified to account for these properties. Recent evidence suggests that protection 
might be associated with conformational epitopes. Linear epitopes from TSOL18 were computationally predicted and evaluated for immunogenicity and protection 
against porcine cysticercosis. A synthetic peptide was designed based on predicted linear B cell and T cell epitopes that are exposed on the surface of the 
theoretically modeled structure of TSOL18. Three surface epitopes from TSOL18 were predicted as immunogenic. A peptide comprising a linear arrangement of 
these epitopes was chemically synthesized. The capacity of the synthetic peptide to protect pigs against an oral challenge with Taenia solium proglottids was tested 
in a vaccine trial. The synthetic peptide was able to produce IgG antibodies in pigs and was associated to a reduction of the number of cysts, although was not able 
to provide complete protection, defined as the complete absence of cysts in necropsy. This study demonstrated that B cell and T cell predicted epitopes from 
TSOL18 were not able to completely protect pigs against an oral challenge with Taenia solium proglottids. Therefore, other linear epitopes or eventually 
conformational epitopes may be responsible for the protection conferred by TSOL18. 
 
 
 
 
Background: 
Taeniasis and cysticercosis are infectious parasitic diseases caused by different 
stages of the tapeworm Taenia solium. An infection with the larval stage in 
humans frequently causes neurocysticercosis, which is an important contributor 
to neurological morbidity in developing countries [1], and a presumable 
principal cause of acquired epilepsy in the world [1, 2]. Given the essential role 
of the pig as the obligate intermediate host, porcine vaccines are promising 
tools in a sustained control of taeniasis/cysticercosis and are crucial to achieve 
possible eradication of this disease. TSOL18 is a recombinant protein which 
has been shown repeatedly to be highly protective when used as a vaccine 
against T. solium infection in pigs [3, 4]. TSOL18, along with other oncosphere 
antigens, has previously been identified as comprising a fibronectin type III 
domain but no specific role has been attributed yet [5]. It would be of great 
value if the protective epitopes associated with this protein were known and, if 
they could be produced synthetically, this would be likely to offer cost and 
quality consistency advantages over the current vaccine that is produced in 
Escherichia coli [3].  
 
Synthetic peptides are being tested as potential vaccines in a wide range of 
infectious diseases [6]. It has been shown that the use of synthetic 
peptides/epitopes could offer an important contribution to protection against T. 
solium cysticercosis in pigs [7-9]. Current immunoinformatics tools are able to 
predict human B cell and T cell linear epitopes with high accuracy. These tools 
are playing an important role in understanding the molecular basis of immunity 
and notably in the development of peptide vaccines, immunotherapy against 
cancer and autoimmune diseases [10-14]. Similar immunoinformatics 
approaches are being developed for other organisms, and will constitute the 
basis for the design of new generation epitope vaccines. This manuscript 
concerns the computational prediction of immunogenic epitopes of the 
TSOL18 protein from T. solium and the design of a synthetic peptide vaccine 
candidate. We hypothesize that TSOL18 comprises a linear epitope able to 
protect pigs against an oral challenge with proglottids with an efficacy close to 
100%. We used molecular modeling and immunoinformatics tools to predict 
linear B cell and T cell immunogenic epitopes of TSOL18. The theoretically 
predicted structure of TSOL18 was used to identify the epitopes exposed on the 
protein surface. A synthetic peptide encompassing three predicted epitopes was 
predicted and tested in a porcine vaccine trial.  
 
Methodology: 
Cellular localization of TSOL18: 
The amino acid sequence of TSOL18 was obtained from the Genbank 
(accession code AF017788). The prediction of the cellular localization was 
performed with the web servers TMHMM [15] and TMPred [16]. The presence 
of a signal peptide was tested with SignalP V1.1 [17]. Transmembrane helices BIOINFORMATION  open access 
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were predicted by HMMTOP [18], SOSUI [19], TMpred [16], TopPred [20] 
and PredictProtein [21]. The hydrophobicity profile of TSOL18 was predicted 
with ProtScale [22] using the Kyte-Dolittle scale [23]. 
 
Structural model building: 
TSOL18 does not yet have any crystallized homologue protein. The TSOL18 
structure was modeled by threading using servers Fugue [24] and 3D-PSSM 
[25, 26]. The amino acid sequence used to model the structure did not include 
the signal peptide. To correct the integrity of the threaded structure, internal 
discontinuities of the amino acid sequence were manually linked and missing 
amino acids in the carboxy- and amino- terminals were introduced as random 
coils. This was done using Swisspdbviewer [27]  and Chimera [28]. The 
structure was refined by energy minimization using the steepest descent 
approach. Further refinement was performed with a 1 ns run of molecular 
dynamics (MD) by means of an explicit periodic box, with water molecules 
and using the GROMACS software package with the force field GROMOS96 
G43a1 [29] 
 
Immunogenic and protective linear epitopes: 
Immunoinformatics approaches to predict linear epitopes are well developed 
for the human HLA-DR restriction element. The prediction of linear epitopes in 
porcine proteins should be done using the SLA-DR molecule; however, the 
immunoinformatics tools for pigs have not been developed yet. HLA and SLA 
are homologues molecules but the range of diversity within the peptide binding 
grooves is not identical. However, given the similarity between the human and 
porcine immune systems and the similarity of their major histocompatibility 
complex, it is likely that immunogenic epitopes might be shared [30]. As a first 
approach, potentially immunogenic porcine epitopes will be identified with 
human immunoinformatics tools. The prediction of TSOL18 B cell epitopes 
was performed with the web server ABCpred [12]. Recurrent neural network 
score was calculated for each 10-amino acid length peptide. The B cell 
predicted epitopes above threshold value (0.45) were chosen. Linear T cell 
epitopes were identified as a first approximation, by prediction of human MHC 
class II linear epitopes with the web server Propred [31]. An immunogenicity 
score was estimated as the frequency in which an epitope was classified as 
immunogenic, among the total number of MHC alleles. We considered this 
probability as the MHC-II immunogenicity index. The accessibility to the 
solvent of each amino acid residue was calculated from the TSOL18 structure 
using the Lee and Richards algorithm implemented in the program ASAView 
[32]. We selected the accessible residues as those with a solvent accessibility 
beyond 30%. Accessible epitopes with the highest scores were considered as 
potentially protective.  
 
Multiepitopic peptide design: 
Three epitopes were selected and were associated to a random-coil in the 
TSOL18 theoretical structure. A peptide comprising the three selected epitopes 
was designed. The secondary structure of the peptide was monitored during a 1 
ns MD run in a water periodic box at 310 K. We confirmed that the peptide 
showed a random coil structure during the 1 ns MD run. The selected peptide 
was chemically synthesized with 95% purity and lyophilized (Alpha Diagnostic 
Intl. Inc, San Antonio, TX). The peptide was synthesized and conjugated to 
Keyhole Limpet Hemocyanin (KLH).  
 
Vaccine trial: 
The synthetic peptide conjugated to KLH was used to immunize pigs. The 
vaccinated group consisted of four two-month old female pigs that received 
three doses. Each of the three doses included 2 ml of antigen (0.15 mg/ml) with 
1 mg saponin as adjuvant in PBS. The placebo group consisted of five pigs of 
similar ages, two male and three female. For this group each of the three doses 
consisted of 2 ml PBS, KLH (0.3 mg), and 1 mg saponin. In all cases the 
second dose was given 2 weeks after the first dose and the third dose was given 
1 week after the second dose. Animals were challenged by oral infection with 
one gravid proglottid 15 days after the third dose. Gravid proglottids were 
obtained from two different tapeworms and were evenly distributed between 
the vaccinated and placebo groups. We collected pre-immune and post-immune 
sera. The latter was collected the day before challenge. Ninety days after the 
challenge, the pigs were humanely euthanized and the entire carcass and brain 
were examined for the presence of cysticerci [33, 34]. Cysts were classified as 
either viable, if a defined cyst structure with liquid content was still present, or 
degenerated, if this had been replaced by semisolid contents or inflammatory 
scar tissue [34]. The collected sera were evaluated using an ELISA assay to test 
the reaction against the peptide, as described previously [35, 36]. The ELISA 
assay used 1 μg/ml of peptide as antigen. Sera were diluted 1/100. A 1/2000 
dilution of anti-pig-IgG-conjugated with peroxidase (Bio-Rad Laboratories, 
Rockville Centre, NY) was used.   
 
Data analysis: 
The number of healthy and degenerated cysts and the number of scars were 
compared between the vaccinated and placebo groups. Means and 95% 
confidence intervals were calculated based on a Poisson distribution. To 
account for over dispersion and to adjust for the age and sex of the pigs, as well 
as the identity of the taenia used for the infection, the number of cysts was 
modeled in a multiple Negative Binomial regression. A paired t-test and non-
parametrical tests were used to compare the ELISA OD means between the 
pre-immune and post-immune sera.  
 
 
Figure 1: Theoretical structure predicted for TSOL18 of Taenia solium (a) 
Ribbon representation, (b) surface representation. In color, the selected 
epitopes: Blue (Ep1) (EEIKVKVEK), green (Ep2) (VIIRDL), and red (Ep3) 
(IFVPYLRCFAL). 
 
Results and Discussion: 
A signal peptide including the first 18 amino acids (MVCRFALIF 
LVAVVLASG) was predicted. No trans-membrane helices were detected, and 
an average hydrophobicity of 0.07 was estimated in the Kyte-Dolittle scale. 
This confirms previous studies that showed TSOL18 being a secreted protein 
[3]. The amino acid sequence of TSOL18 did not have any homologue with a 
known structure (E-value =2.9 for the best hit), and no other putative functional 
conserved domain except fibronectin type III, was assigned. The 3D structure 
was obtained using as query a fibronectin type III structural protein (PDB Id: 
1QG3). The modeled structure of TSOL18 comprises a fibronectin type III 
domain (Figure 1) as was previously proposed [3]. HP6 from Taenia saginata 
was associated with a fibronectin type III domain and was described as an 
adherence protein [37]. TSOL18 and HP6 are homologs according to the high 
similarity shared (61%) [3]. Our independent analysis after a rigorous structure 
refinement approach confirms the association of TSOL18 with a fibronectin 
type III domain. These predictions suggest that TSOL18 may participate in the 
intestinal adherence of oncospheres, an event preceding the intestinal wall 
degradation and penetration. It can be speculated that the protection conferred 
by TSOL18 could be associated to the prevention of the adherence of the 
oncosphere to the intestinal wall mediated by the action of IgA antibodies at 
the intestinal epithelium. The three best B cell linear epitopes showing the 
highest score and that are exposed on the surface of TSOL18 structure, 
coincidently resulted to be predicted as potential linear T cell epitopes too. The 
epitope NH3-EEIKVKVEK-COOH in position 56-64 (Ep1) had the highest B 
cell epitope score (0.83). The epitope NH3-VIIRDL-COOH in position 83-88 
(Ep2) had the second highest score (0.72) and was exposed on the protein 
surface. The third surface epitope selected was NH3-IFVPYLRCFAL-COOH 
in position 26-36 (Ep3), with a score of 0.46, and also was exposed on the 
protein surface. The fusion peptide (NH3_EEIKVKVEKIFVPYLRC 
FALVIIRDL_COOH) preserved the average random coil secondary structure 
during the 1 ns MD run and was selected as the antigen for the vaccine trial. In 
the vaccine trial all challenged animals harbored live parasites; therefore, a 
complete protection was not observed in any given pig. Complete protection is 
understood as an absolute absence of cysts in the vaccinated group. Although, a 
trend towards reduced number of total cysticerci in the vaccinated group BIOINFORMATION  open access 
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compared to the placebo group was observed. In all vaccinated animals, the 
ELISA readings confirmed an increased reactivity of the post-immune sera 
compared to the pre-immune sera against the vaccine antigen. The identity of 
the taenia was significantly associated with the total number of cysts (P < 
0.0001), suggesting that the infectivity of the two tapeworms was different. 
After adjusting for the taenia identity, the age and sex of the pig, the number of 
total cysts, viable cysts and scars, were significantly lower in the vaccinated 
group (P = 0.018, P=0.001, and P=0.001 respectively) (Table 1 see 
supplementary material). No significant difference was observed in the 
number of degenerated cysts between the placebo and vaccinated groups 
(P=0.156). For some time, available evidence has suggested that the protective 
epitopes of TSOL18 were likely to be conformational, based on similarities 
with the EG95 vaccine protein [38, 39]. These studies examined the nature of 
the antigenic epitopes of the protective oncosphere protein EG95 of 
Echinococcus granulosus, which suggested that its host-protective epitopes are 
conformational rather than linear [38, 39]. EG95 and TSOL18 are both host-
protective oncosphere antigens of taeniid cestode parasites and both contain a 
fibronectin type III domain. Supporting these results, recently, Assana et al. 
(2010) suggested that the principal antibody specificities raised by TSOL18 in 
pigs is against conformational epitopes [40]. Although no porcine-specific 
MHC-epitopes prediction tools are available, the prediction of TSOL18 
immunogenic epitopes using human MHC class II profiles is justified by the 
high level of similarity between human and porcine class II molecules antigens 
[30]. It would be important to do further studies to develop a porcine-specific 
MHC matrix to have a more accurate prediction of SLA epitopes. The epitopes 
predicted in the present study, were identified using a hypothetical structure 
model of the TSOL18. It is possible that the model did not perfectly reflect the 
real structure of the protein. It would be important to determine a 
crystallographic 3-dimensional structure of TSOL18 in order to obtain more 
accurate predictions. 
 
Conclusion: 
A synthetic peptide comprising the best theoretically predicted protective linear 
epitopes using immunoinformatics tools based on human MHC matrixes failed 
to completely protect pigs against porcine cysticercosis. Although a trend to a 
decreased number of total cysts was observed in the vaccinated group. It is 
likely that the total protection conferred by TSOL18 could be associated with 
conformational epitopes rather than with linear epitopes.  
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Supplementary material: 
 
Table 1: Results of the immunization trial measured during necropsy of pigs.  
Group pig 
(id) 
Age 
(days) 
Sex Taenia
a  Viable cysts   Degenerated cysts  Total cysts  Scars   
 
Placebo                
1P 200  F  2  2 
b  793.6 
[769.1, 
818.7] 
c 1419 
b    857.2 
[831.7, 
883.2] 
c 1421 
b 1650.8 
[1615.4, 
1686.8] 
c  3 
b 20 
[16.3, 
24.0]   
c
2P  199  M  2  3922   43    3965   7   
3P  198  F  2  2    1582   1584   70   
4P  200  F  1  0    1104   1104   20   
5P  199  M  1  42    138   180   0   
V a c c i n e                                    
6V 200  F  2  554    166.3 
[153.9, 
179.4]
  
 850   359.3 
[340.9, 
378.3] 
 1404   525.5 
[503.3, 
548.4] 
 0   5.25 
[3.30, 
8.0]
  
 
7V  198  F  2  0     346    346    9     
8V 199  F  1  108   
c 187   
c 295   
c 8   
c 
9V  198  F  1  3     54     57     4     
 P-value        0.001  0.156  0.018  0.001   
aTaenia used in challenge. 
bNumber of cysts and scars and its measure of variation. 
cMean and 95% CI for a Poisson distribution. P-values correspond to the 
adjusted comparisons between the placebo and the vaccinated group with multiple
 negative binomial regressions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 